Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. GLUT5-overexpression-related tumorigenic implications.Molecular medicine (Cambridge, Mass.) · 2024
   Review
2. Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer.iScience · 2023
   Article
3. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients.Cancer cell international · 2019
   Article
4. Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.Therapeutic advances in medical oncology · 2017
   Review
5. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
   Article
6. Metabolic reprogramming in clear cell renal cell carcinoma.Nature reviews. Nephrology · 2017
   Review
7. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.Urologic oncology · 2017
   Review
8. Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.World journal of urology · 2017
   Article
9. Precision medicine from the renal cancer genome.Nature reviews. Nephrology · 2016
   Review
10. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.Oncotarget · 2016
    Article
11. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.Journal of the American Society of Nephrology : JASN · 2016
    Review
12. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.PloS one · 2016
    Article
13. Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma.Oncoimmunology
    Article

Corrections and comments

• Comment on
  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.2015
• Comment on
  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.2015

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as